Global Hormone Refractory Breast Cancer Market
Global Hormone Refractory Breast Cancer Market

Hormone Refractory Breast Cancer Comprehensive Study by Treatment (Hormone receptor-based therapy, Tumor markers therapy, Gene expression therapy, Gene mutation therapy), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Diagnosis (CT Scan, MRI, Biopsy, Others) Players and Region - Global Market Outlook to 2025

Hormone Refractory Breast Cancer Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jun 2020 Edition 217 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

According to WHO, breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer that is approximately 15% of all cancer deaths among women as per world health organization. Breast cancer is cancer that forms a tumor in the cells of the breast. Hormone therapies are commonly used for the treatment of breast cancer, which subsequently leads to resistance after the continuous use of hormone therapy.

The market study is being classified and major geographies with country level break-up.

AstraZeneca plc (United Kingdom), Bluefish Pharmaceuticals AB (Sweden), AmpliMed Corporation (United Kingdom), F. Hoffmann-La Roche Ltd. (Switzerland), Neopharm Ltd. (Israel), NeoCorp GmbH (Germany) and Boehringer Ingelheim GmbH (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Hormone Refractory Breast Cancer market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Hormone Refractory Breast Cancer market by Type, Application and Region.

On the basis of geography, the market of Hormone Refractory Breast Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Breast Cancer Worldwide
  • High Demand for Effective Cancer Treatment

Market Trend
  • Increased Research and Development Activities
  • Government Initiatives for Cancer Research

Restraints
  • Less Awareness about Cancer Treatment in Some Regions

Opportunities
  • Growth in the Health Care Industry
  • Huge Investments By Major Players

Challenges
  • Stringent Government Rules and Regulations





Key Target Audience
Pharmaceutical Companies, Raw Material Suppliers, Distributors, Emerging Companies and End-users

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Hormone receptor-based therapy
  • Tumor markers therapy
  • Gene expression therapy
  • Gene mutation therapy

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Diagnosis
  • CT Scan
  • MRI
  • Biopsy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Breast Cancer Worldwide
      • 3.2.2. High Demand for Effective Cancer Treatment
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Activities
      • 3.4.2. Government Initiatives for Cancer Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hormone Refractory Breast Cancer, by Treatment, End-users, Diagnosis and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Hormone Refractory Breast Cancer (Value)
      • 5.2.1. Global Hormone Refractory Breast Cancer by: Treatment (Value)
        • 5.2.1.1. Hormone receptor-based therapy
        • 5.2.1.2. Tumor markers therapy
        • 5.2.1.3. Gene expression therapy
        • 5.2.1.4. Gene mutation therapy
      • 5.2.2. Global Hormone Refractory Breast Cancer by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Hormone Refractory Breast Cancer by: Diagnosis (Value)
        • 5.2.3.1. CT Scan
        • 5.2.3.2. MRI
        • 5.2.3.3. Biopsy
        • 5.2.3.4. Others
      • 5.2.4. Global Hormone Refractory Breast Cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Hormone Refractory Breast Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AstraZeneca plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bluefish Pharmaceuticals AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AmpliMed Corporation (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Neopharm Ltd. (Israel)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NeoCorp GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Boehringer Ingelheim GmbH (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hormone Refractory Breast Cancer Sale, by Treatment, End-users, Diagnosis and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Hormone Refractory Breast Cancer (Value)
      • 7.2.1. Global Hormone Refractory Breast Cancer by: Treatment (Value)
        • 7.2.1.1. Hormone receptor-based therapy
        • 7.2.1.2. Tumor markers therapy
        • 7.2.1.3. Gene expression therapy
        • 7.2.1.4. Gene mutation therapy
      • 7.2.2. Global Hormone Refractory Breast Cancer by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Hormone Refractory Breast Cancer by: Diagnosis (Value)
        • 7.2.3.1. CT Scan
        • 7.2.3.2. MRI
        • 7.2.3.3. Biopsy
        • 7.2.3.4. Others
      • 7.2.4. Global Hormone Refractory Breast Cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hormone Refractory Breast Cancer: by Treatment(USD Million)
  • Table 2. Hormone Refractory Breast Cancer Hormone receptor-based therapy , by Region USD Million (2014-2019)
  • Table 3. Hormone Refractory Breast Cancer Tumor markers therapy , by Region USD Million (2014-2019)
  • Table 4. Hormone Refractory Breast Cancer Gene expression therapy , by Region USD Million (2014-2019)
  • Table 5. Hormone Refractory Breast Cancer Gene mutation therapy , by Region USD Million (2014-2019)
  • Table 6. Hormone Refractory Breast Cancer: by End-users(USD Million)
  • Table 7. Hormone Refractory Breast Cancer Hospitals , by Region USD Million (2014-2019)
  • Table 8. Hormone Refractory Breast Cancer Clinics , by Region USD Million (2014-2019)
  • Table 9. Hormone Refractory Breast Cancer Ambulatory Surgical Centres , by Region USD Million (2014-2019)
  • Table 10. Hormone Refractory Breast Cancer Others , by Region USD Million (2014-2019)
  • Table 11. Hormone Refractory Breast Cancer: by Diagnosis(USD Million)
  • Table 12. Hormone Refractory Breast Cancer CT Scan , by Region USD Million (2014-2019)
  • Table 13. Hormone Refractory Breast Cancer MRI , by Region USD Million (2014-2019)
  • Table 14. Hormone Refractory Breast Cancer Biopsy , by Region USD Million (2014-2019)
  • Table 15. Hormone Refractory Breast Cancer Others , by Region USD Million (2014-2019)
  • Table 16. South America Hormone Refractory Breast Cancer, by Country USD Million (2014-2019)
  • Table 17. South America Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 18. South America Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 19. South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 20. Brazil Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 21. Brazil Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 22. Brazil Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 23. Argentina Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 24. Argentina Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 25. Argentina Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 26. Rest of South America Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 27. Rest of South America Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 28. Rest of South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 29. Asia Pacific Hormone Refractory Breast Cancer, by Country USD Million (2014-2019)
  • Table 30. Asia Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 31. Asia Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 32. Asia Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 33. China Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 34. China Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 35. China Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 36. Japan Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 37. Japan Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 38. Japan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 39. India Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 40. India Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 41. India Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 42. South Korea Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 43. South Korea Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 44. South Korea Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 45. Taiwan Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 46. Taiwan Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 47. Taiwan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 48. Australia Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 49. Australia Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 50. Australia Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 51. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 52. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 53. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 54. Europe Hormone Refractory Breast Cancer, by Country USD Million (2014-2019)
  • Table 55. Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 56. Europe Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 57. Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 58. Germany Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 59. Germany Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 60. Germany Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 61. France Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 62. France Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 63. France Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 64. Italy Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 65. Italy Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 66. Italy Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 67. United Kingdom Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 68. United Kingdom Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 69. United Kingdom Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 70. Netherlands Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 71. Netherlands Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 72. Netherlands Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 73. Rest of Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 74. Rest of Europe Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 75. Rest of Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 76. MEA Hormone Refractory Breast Cancer, by Country USD Million (2014-2019)
  • Table 77. MEA Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 78. MEA Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 79. MEA Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 80. Middle East Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 81. Middle East Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 82. Middle East Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 83. Africa Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 84. Africa Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 85. Africa Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 86. North America Hormone Refractory Breast Cancer, by Country USD Million (2014-2019)
  • Table 87. North America Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 88. North America Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 89. North America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 90. United States Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 91. United States Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 92. United States Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 93. Canada Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 94. Canada Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 95. Canada Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 96. Mexico Hormone Refractory Breast Cancer, by Treatment USD Million (2014-2019)
  • Table 97. Mexico Hormone Refractory Breast Cancer, by End-users USD Million (2014-2019)
  • Table 98. Mexico Hormone Refractory Breast Cancer, by Diagnosis USD Million (2014-2019)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Hormone Refractory Breast Cancer: by Treatment(USD Million)
  • Table 107. Hormone Refractory Breast Cancer Hormone receptor-based therapy , by Region USD Million (2020-2025)
  • Table 108. Hormone Refractory Breast Cancer Tumor markers therapy , by Region USD Million (2020-2025)
  • Table 109. Hormone Refractory Breast Cancer Gene expression therapy , by Region USD Million (2020-2025)
  • Table 110. Hormone Refractory Breast Cancer Gene mutation therapy , by Region USD Million (2020-2025)
  • Table 111. Hormone Refractory Breast Cancer: by End-users(USD Million)
  • Table 112. Hormone Refractory Breast Cancer Hospitals , by Region USD Million (2020-2025)
  • Table 113. Hormone Refractory Breast Cancer Clinics , by Region USD Million (2020-2025)
  • Table 114. Hormone Refractory Breast Cancer Ambulatory Surgical Centres , by Region USD Million (2020-2025)
  • Table 115. Hormone Refractory Breast Cancer Others , by Region USD Million (2020-2025)
  • Table 116. Hormone Refractory Breast Cancer: by Diagnosis(USD Million)
  • Table 117. Hormone Refractory Breast Cancer CT Scan , by Region USD Million (2020-2025)
  • Table 118. Hormone Refractory Breast Cancer MRI , by Region USD Million (2020-2025)
  • Table 119. Hormone Refractory Breast Cancer Biopsy , by Region USD Million (2020-2025)
  • Table 120. Hormone Refractory Breast Cancer Others , by Region USD Million (2020-2025)
  • Table 121. South America Hormone Refractory Breast Cancer, by Country USD Million (2020-2025)
  • Table 122. South America Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 123. South America Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 124. South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 125. Brazil Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 126. Brazil Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 127. Brazil Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 128. Argentina Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 129. Argentina Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 130. Argentina Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 131. Rest of South America Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 132. Rest of South America Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 133. Rest of South America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 134. Asia Pacific Hormone Refractory Breast Cancer, by Country USD Million (2020-2025)
  • Table 135. Asia Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 136. Asia Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 137. Asia Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 138. China Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 139. China Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 140. China Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 141. Japan Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 142. Japan Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 143. Japan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 144. India Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 145. India Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 146. India Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 147. South Korea Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 148. South Korea Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 149. South Korea Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 150. Taiwan Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 151. Taiwan Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 152. Taiwan Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 153. Australia Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 154. Australia Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 155. Australia Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 156. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 157. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 158. Rest of Asia-Pacific Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 159. Europe Hormone Refractory Breast Cancer, by Country USD Million (2020-2025)
  • Table 160. Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 161. Europe Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 162. Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 163. Germany Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 164. Germany Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 165. Germany Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 166. France Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 167. France Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 168. France Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 169. Italy Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 170. Italy Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 171. Italy Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 172. United Kingdom Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 173. United Kingdom Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 174. United Kingdom Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 175. Netherlands Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 176. Netherlands Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 177. Netherlands Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 178. Rest of Europe Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 179. Rest of Europe Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 180. Rest of Europe Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 181. MEA Hormone Refractory Breast Cancer, by Country USD Million (2020-2025)
  • Table 182. MEA Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 183. MEA Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 184. MEA Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 185. Middle East Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 186. Middle East Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 187. Middle East Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 188. Africa Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 189. Africa Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 190. Africa Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 191. North America Hormone Refractory Breast Cancer, by Country USD Million (2020-2025)
  • Table 192. North America Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 193. North America Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 194. North America Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 195. United States Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 196. United States Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 197. United States Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 198. Canada Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 199. Canada Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 200. Canada Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 201. Mexico Hormone Refractory Breast Cancer, by Treatment USD Million (2020-2025)
  • Table 202. Mexico Hormone Refractory Breast Cancer, by End-users USD Million (2020-2025)
  • Table 203. Mexico Hormone Refractory Breast Cancer, by Diagnosis USD Million (2020-2025)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hormone Refractory Breast Cancer: by Treatment USD Million (2014-2019)
  • Figure 5. Global Hormone Refractory Breast Cancer: by End-users USD Million (2014-2019)
  • Figure 6. Global Hormone Refractory Breast Cancer: by Diagnosis USD Million (2014-2019)
  • Figure 7. South America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 8. Asia Pacific Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 9. Europe Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 10. MEA Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 11. North America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 12. Global Hormone Refractory Breast Cancer share by Players 2019 (%)
  • Figure 13. Global Hormone Refractory Breast Cancer share by Players (Top 3) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 16. AstraZeneca plc (United Kingdom) Revenue: by Geography 2019
  • Figure 17. Bluefish Pharmaceuticals AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 18. Bluefish Pharmaceuticals AB (Sweden) Revenue: by Geography 2019
  • Figure 19. AmpliMed Corporation (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AmpliMed Corporation (United Kingdom) Revenue: by Geography 2019
  • Figure 21. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 23. Neopharm Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Neopharm Ltd. (Israel) Revenue: by Geography 2019
  • Figure 25. NeoCorp GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. NeoCorp GmbH (Germany) Revenue: by Geography 2019
  • Figure 27. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2019
  • Figure 29. Global Hormone Refractory Breast Cancer: by Treatment USD Million (2020-2025)
  • Figure 30. Global Hormone Refractory Breast Cancer: by End-users USD Million (2020-2025)
  • Figure 31. Global Hormone Refractory Breast Cancer: by Diagnosis USD Million (2020-2025)
  • Figure 32. South America Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 33. Asia Pacific Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 34. Europe Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 35. MEA Hormone Refractory Breast Cancer Share (%), by Country
  • Figure 36. North America Hormone Refractory Breast Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • AstraZeneca plc (United Kingdom)
  • Bluefish Pharmaceuticals AB (Sweden)
  • AmpliMed Corporation (United Kingdom)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Neopharm Ltd. (Israel)
  • NeoCorp GmbH (Germany)
  • Boehringer Ingelheim GmbH (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation